3
Announcements
Trials
Browse
Landscape
Phase
Phase 3
1
Status
Terminated
1
Sponsor Class
INDUSTRY
1
Study Type
Interventional
1
Sponsor
Cancer Type
Thoracic
1
Sarcoma
1
Breast
1
Conditions
Lung Neoplasms
2
Carcinoma, Non-Small-Cell Lung
2
Thoracic Neoplasms
1
Respiratory Tract Neoplasms
1
Respiratory Tract Diseases
1
Neoplasms by Site
1
Neoplasms
1
Lung Diseases
1
Carcinoma
1
Bronchial Neoplasms
1
Interventions
pembrolizumab
61
Carboplatin
44
Pemetrexed
31
Paclitaxel
31
Docetaxel
31
Cisplatin
27
Gemcitabine
24
Nivolumab
23
Erlotinib Hydrochloride
21
Bevacizumab
18
Ipilimumab
11
osimertinib
10
Drug Therapy
10
atezolizumab
9
Radiosurgery
9
Cyclophosphamide
9
Cetuximab
9
Blood Specimen Collection
9
durvalumab
8
cemiplimab
8
Radiotherapy
8
budigalimab
7
Fluorouracil
7
Dexamethasone
7
trametinib
6
fludarabine
6
dostarlimab
6
avelumab
6
Taxes
6
130-nm albumin-bound paclitaxel
6
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
1 trials
Recent
Start date
Enrollment
Neoplasms
×
patritumab
×
Thoracic
×
Clear all
NCT02134015
2018-01-23
HER3-Lung
Daiichi Sankyo
Phase 3
Terminated
145 enrolled
20 charts